These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 10639349)

  • 1. Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates.
    Boyle-Vavra S; Berke SK; Lee JC; Daum RS
    Antimicrob Agents Chemother; 2000 Feb; 44(2):272-7. PubMed ID: 10639349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U.S. hospitals.
    Hubert SK; Mohammed JM; Fridkin SK; Gaynes RP; McGowan JE; Tenover FC
    J Clin Microbiol; 1999 Nov; 37(11):3590-3. PubMed ID: 10523558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate.
    Boyle-Vavra S; Carey RB; Daum RS
    J Antimicrob Chemother; 2001 Nov; 48(5):617-25. PubMed ID: 11679550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds.
    Pfeltz RF; Singh VK; Schmidt JL; Batten MA; Baranyk CS; Nadakavukaren MJ; Jayaswal RK; Wilkinson BJ
    Antimicrob Agents Chemother; 2000 Feb; 44(2):294-303. PubMed ID: 10639353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals.
    Cartolano GL; Cheron M; Benabid D; Leneveu M; Boisivon A;
    Clin Microbiol Infect; 2004 May; 10(5):448-51. PubMed ID: 15113324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The VISA/GISA problem: therapeutic implications.
    Liñares J
    Clin Microbiol Infect; 2001; 7 Suppl 4():8-15. PubMed ID: 11688538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate clinical Staphylococcus aureus isolates.
    Boyle-Vavra S; Labischinski H; Ebert CC; Ehlert K; Daum RS
    Antimicrob Agents Chemother; 2001 Jan; 45(1):280-7. PubMed ID: 11120978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis and validation of different assays for glycopeptide susceptibility among methicillin-resistant Staphylococcus aureus strains.
    Bernard L; Vaudaux P; Rohner P; Huggler E; Armanet M; Pittet D; Lew DP; Schrenzel J
    J Microbiol Methods; 2004 May; 57(2):231-9. PubMed ID: 15063063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin.
    Sakoulas G; Eliopoulos GM; Moellering RC; Wennersten C; Venkataraman L; Novick RP; Gold HS
    Antimicrob Agents Chemother; 2002 May; 46(5):1492-502. PubMed ID: 11959587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus.
    Vaudaux P; Huggler E; Bernard L; Ferry T; Renzoni A; Lew DP
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3861-70. PubMed ID: 20547791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA.
    Yusof A; Engelhardt A; Karlsson A; Bylund L; Vidh P; Mills K; Wootton M; Walsh TR
    J Clin Microbiol; 2008 Sep; 46(9):3042-7. PubMed ID: 18596146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureus.
    Fitzgibbon MM; Rossney AS; O'Connell B
    J Clin Microbiol; 2007 Oct; 45(10):3263-9. PubMed ID: 17687008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus.
    Cui L; Ma X; Sato K; Okuma K; Tenover FC; Mamizuka EM; Gemmell CG; Kim MN; Ploy MC; El-Solh N; Ferraz V; Hiramatsu K
    J Clin Microbiol; 2003 Jan; 41(1):5-14. PubMed ID: 12517819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital.
    Garnier F; Chainier D; Walsh T; Karlsson A; Bolmström A; Grelaud C; Mounier M; Denis F; Ploy MC
    J Antimicrob Chemother; 2006 Jan; 57(1):146-9. PubMed ID: 16286482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals.
    Nonhoff C; Denis O; Struelens MJ
    Clin Microbiol Infect; 2005 Mar; 11(3):214-20. PubMed ID: 15715719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus.
    Koehl JL; Muthaiyan A; Jayaswal RK; Ehlert K; Labischinski H; Wilkinson BJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3749-57. PubMed ID: 15388430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA).
    Voss A; Mouton JW; van Elzakker EP; Hendrix RG; Goessens W; Kluytmans JA; Krabbe PF; de Neeling HJ; Sloos JH; Oztoprak N; Howe RA; Walsh TR
    Ann Clin Microbiol Antimicrob; 2007 Sep; 6():9. PubMed ID: 17892555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.
    Aeschlimann JR; Allen GP; Hershberger E; Rybak MJ
    Antimicrob Agents Chemother; 2000 Nov; 44(11):2991-8. PubMed ID: 11036011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo emergence of subpopulations expressing teicoplanin or vancomycin resistance phenotypes in a glycopeptide-susceptible, methicillin-resistant strain of Staphylococcus aureus.
    Vaudaux P; Francois P; Berger-Bächi B; Lew DP
    J Antimicrob Chemother; 2001 Feb; 47(2):163-70. PubMed ID: 11157900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of isolates with reduced glycopeptide susceptibility in orthopedic device-related infections due to methicillin-resistant Staphylococcus aureus.
    Vaudaux P; Ferry T; Uçkay I; François P; Schrenzel J; Harbarth S; Renzoni A
    Eur J Clin Microbiol Infect Dis; 2012 Dec; 31(12):3367-74. PubMed ID: 22833247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.